Claude Science

News

Using Claude Science, Claude agents designed high-affinity protein binders for a range of targets, outperforming human experts in some cases.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.